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Recent advances in next-generation sequencing technologies have transformed the
genetics study of human diseases; this is an era of unprecedented productivity. Exome
sequencing, the targeted sequencing of the protein-coding portion of the human genome,
has been shown to be a powerful and cost-effective method for detection of disease
variants underlying Mendelian disorders. Increasing effort has been made in the interest
of the identiﬁcation of rare variants associated with complex traits in sequencing studies.
Here we provided an overview of the application ﬁelds for exome sequencing in human
diseases.We describe a general framework of computation and bioinformatics for handling
sequencing data. We then demonstrate data quality and agreement between exome
sequencing and exomemicroarray (chip) genotypes using data collected on the same set of
subjects in a genetic study of panic disorder. Our results show that, in sequencing data, the
data quality was generally higher for variants within the exonic target regions, compared to
that outside the target regions, due to the target enrichment.We also compared genotype
concordance for variant calls obtained by exome sequencing vs. exome genotyping
microarrays.The overall consistency rate was >99.83% and the heterozygous consistency
rate was >97.55%. The two platforms share a large amount of agreement over low
frequency variants in the exonic regions, while exome sequencing provides much more
information on variants not included on exome genotyping microarrays. The results
demonstrate that exome sequencing data are of high quality and can be used to investigate
the role of rare coding variants in human diseases.
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INTRODUCTION
Determining the genetic basis of human diseases is one of the
major research areas in medical science (McCarthy et al., 2008).
The allelic spectrum of variants underlying human disorders has
long been a topic of discussion and speculation (Pritchard, 2001;
Reich and Lander, 2001). Despite signiﬁcant progress in the identi-
ﬁcation of large numbers of loci that contribute to complex traits
in genome-wide association studies (GWAS), only a small frac-
tion of the observed heritability is explained by the conﬁrmed
(genomewide-signiﬁcant) common variants (Manolio et al., 2009;
Schork et al., 2009). A recent study (Yang et al., 2010) demon-
strated that the heritability estimation can be improved by using all
genomewide common single nucleotide polymorphisms (SNPs)
relative to that using only identiﬁed genomewide-signiﬁcant SNPs,
and this accounts for some of the heritability that is “missing.”The
advent of massively parallel sequencing technologies has trans-
formed the ﬁeld of human genetics and substantially reduced the
cost of sequencing large genomic regions relative to the traditional
Sanger sequencing (Mardis, 2008; Ansorge, 2009; Metzker, 2010).
This allows researchers to investigate variants from a wide range of
allelic spectrum, including variants that are too rare for inclusion
on microarrays and new mutations; and higher-level structural
variants. Thus, sequencing approaches have the potential to
explain some of the missing heritability from GWAS for com-
plex traits, through identiﬁcation of rare variants and structural
variations (Manolio et al., 2009; Eichler et al., 2010). However, it
is still ﬁnancially impractical, for most laboratories, to perform
whole-genome sequencing for large numbers of subjects at sufﬁ-
ciently high coverage, in order to complete valid large-scale genetic
association studies of complex traits.
A more economical approach to gene discovery is to focus
on functional coding regions of the human genome. The exome
represents about 1% of the human genome with approximately
30 million base pairs, but accounts for about 85% of muta-
tions identiﬁed in Mendelian diseases (Ng et al., 2009). Recent
developments in high-throughput sequence capturemethods have
made exome sequencing an attractive and practical approach for
investigation of coding variation (Biesecker, 2010; Kaiser, 2010;
Mamanova et al., 2010; Ng et al., 2010a,b). During the past 3 years,
more than 100 genes have been characterized in rare Mendelian
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diseases by the use of whole exome sequencing. Application of this
approach for non-Mendelian phenotypes has been, to date, much
less widespread.
Traditional microarray-based tag SNP genotyping techniques
designed for GWAS target relatively common variants. With the
rich information gathered from sequencing over 12,000 individual
exomes and whole-genome sequences representing multiple eth-
nicities and complex traits, the companies that market genotyping
arrays (chips), Illumina, and Affymetrix, through a collabora-
tion with leading geneticists, have designed exome chips that
contain putative functional exonic variants, with the majority of
them focusing on rare markers selected from sequencing stud-
ies (Exome chip design1). The introduction of exome arrays
has provided a fast and economical platform for genotyping the
included exonic variants, and has to some extent bridged the
gap between traditional genotyping arrays and exome sequenc-
ing of very large numbers of samples, although they bring
with them their own particular technical issues, most partic-
ularly, the inability to query very rare variants or new muta-
tions.
Both exome sequencing and exome genotyping arrays are
designed to investigate coding variation. The current approach
for exome sequencing is based on a probe hybridization method
to select the entire set of human exons as the sequencing tar-
get (Hodges et al., 2007; Gnirke et al., 2009). Although the exonic
regions are the primary target, the efﬁciency of different capture
technologies can affect the amount of information outside tar-
get regions. Currently, there is still a portion of captured DNA
fragments falling into non-coding regions such as introns, intron-
exon boundary regions, and intergenic regions – some of these
regions often contain functional elements. A recent report (Guo
et al., 2012) demonstrated that the small amount of sequenc-
ing data that lies outside the exonic target regions is of high
quality and can be used in genetic studies. In contrast, exome
arrays focus on a ﬁxed set of variants by design. Therefore,
exome sequencing, compared to the use of exome arrays, gen-
erates not only more genetic variations at base-pair resolution
in the coding regions, but also additional, albeit limited, vari-
ant information outside the primary target regions. In this paper,
we ﬁrst provide an overview of the main application ﬁelds for
exome sequencing relative to exome genotyping arrays in human
diseases. Next, we describe the computational and statistical chal-
lenges for handling sequencing data. Then we evaluate the data
quality and agreement between these two platforms using our
exome sequencing and exome microarray data collected on the
same set of subjects. Finally, we discuss some limitations of exome
sequencing.
APPLICATIONS OF EXOME SEQUENCING
Next-generation sequencing (NGS) technologies have been
applied to several important areas including genomes, transcrip-
tomes, epigenomes, and metagenomes (Zhou et al., 2010). Here,
we mainly consider applications of sequencing to the identiﬁ-
cation of genes and mutations that inﬂuence risk for human
diseases.
1http://genome.sph.umich.edu/wiki/Exome_Chip_Design
MENDELIAN DISORDERS
The “traditional” approach to elucidating causes of Mendelian
disorders – or in any event, the ﬁrst generalizable approach to
locate risk genes without prior knowledge – is based on linkage
analysis followed by positional cloning (Botstein and Risch, 2003).
Linkage studies require ascertainment of a sufﬁcient number of
probands with their families, and thus are not suitable for rare
Mendelian diseases where only one or a few individuals may be
sampled. In addition, modest-sized linkage studies are not sen-
sitive enough to detect co-segregation within families in case of
locus heterogeneity and phenotypic heterogeneity. NGS meth-
ods, on the other hand, have the potential to identify all kinds
of genetic variation at base-pair resolution throughout the human
genome in a single experiment (Bamshad et al.,2011; Gilissen et al.,
2011; Ku et al., 2011), and provide an unbiased approach to detect-
ing genetic variation within an individual. Currently sequencing
instruments are still limited by throughput and cost efﬁciency.
Exome sequencing, by capturing the protein-coding portion of the
genome, generates a full picture of variation at functionally impor-
tant regions of the genome (excluding regulatory changes), andhas
now become technically feasible and a more cost-effective strategy
to work out the genetic basis of Mendelian disease. It has been a
proven tool for the identiﬁcation of de novo mutations underlying
some rare monogenic diseases such as Kabuki syndrome (Ng et al.,
2010a) and Miller syndrome (Ng et al., 2010b). Since November
2009, exome sequencing has led to the discovery of more than
100 genes in Mendelian diseases (Rabbani et al., 2012). As the
sequencing cost per base will drop in the near future, we expect
that whole-genome sequencing will be the ultimate approach to
detection of all genomic variations and help us gain more knowl-
edge on the genetics of Mendelian diseases – but even when the
laboratory costs of generating full sequences decrease, there will
still be very substantial informatics costs, which are also much
lower of exome analysis.
COMPLEX DISEASES
Over the past 8 years, the genetics research community has put
a great deal of effort on studies of complex diseases which are
caused by the interplay among multiple behavioral, environmen-
tal, and genetic factors. Association studies have been applied
for decades to investigate the genetics of complex traits (Mar-
ian, 2012). With the advancement of high-throughput genotyping
technologies, GWAS has been the main tool to ﬁnd suscepti-
bility genes based on the principle of linkage disequilibrium at
the population level (Visscher et al., 2012). The development of
SNP arrays genotyping hundreds of thousands or even millions of
markers in a single assay has made GWAS feasible in large-scale
population genetic studies. Since 2005, more than 8,000 loci have
been reported to be associated with various human complex dis-
eases and traits (A catalog of published GWAS2). The selection of
markers investigated in most GWAS is based on the “common dis-
ease, common variant”hypothesis. SNP arrays provide a picture of
genome-wide polymorphism in many individuals (The Interna-
tional HapMap Consortium, 2005, 2007), however, they inevitably
suffer from ascertainment biases favoring SNPs that are common
2http://www.genome.gov/gwastudies
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in the populations for variant discovery (Akey et al., 2003; Clark
et al., 2005). In contrast, gene sequencing provides a more accu-
rate and complete perspective with respect to all polymorphisms
in target regions, or whole-genome (Tennessen et al., 2011). As a
result, the ﬁeld is now shifting toward the study of low frequency
variants under the hypothesis of “common disease, rare variant,”
i.e., multiple rare variants with large effect size are in some cases
the main determinants of complex disease genetic risk (Marian,
2012). Exome genotyping arrays, based on the knowledge attained
from many NGS studies, were designed also to target at a carefully
selected subset of rare coding variants. Currently, exome arrays
have served as a fast and economical tool for the initial investiga-
tion of the role of rare exonic variants in complex diseases (Huyghe
et al., 2013), although more comprehensive evaluation of low fre-
quency variants, copy number variants (CNVs), and structural
variation, is accomplished much more effectively by NGS.
COMPUTATIONAL AND STATISTICAL CHALLENGE OF
SEQUENCING DATA
Next-generation sequencing instruments sequence millions of
short DNA fragments in parallel. Compared to gene chip anal-
ysis, the data generated by sequencing require more sophisticated
bioinformatics and statistical tools. In the identiﬁcation of variants
inNGS studies, the rawdata are pre-processed into nucleotide base
calls called short reads, varying from dozens to hundreds of base
pairs, in the form of a FASTQ ﬁle. To call variants from sequenc-
ing data, many alignment methods and variant callers have been
developed and used to create complex pipelines. A typical pipeline
contains an aligner and a variant caller. The aligner maps each of
the short reads to positions on a reference genome. The result-
ing sequence alignment is stored in a sequence alignment/map
(SAM) or binary alignment/map (BAM) ﬁle (Li et al., 2009a). The
variant caller identiﬁes variant sites where the aligned sequences
deviate from the known sequences at the reference position. The
list of positions is recorded in a variant call format (VCF) ﬁle
(Danecek et al., 2011). Further steps involve ﬁltering and anno-
tation to reduce variant sites to a smaller set of genes (when the
sequence studied is exomic) with possible function and activity.
We will now discuss these steps in detail and review the statistical
strategies for identifying causal variants in human diseases.
ALIGNMENT
“Alignment” is the step of matching short nucleotide reads to a
reference genome. There are various software programs, either
commercially available or freely distributed, that can be used to
perform sequence reads alignment; to name a few, Bowtie/Bowtie2
(Langmead et al., 2009; Langmead and Salzberg, 2012), BWA
(Li and Durbin, 2009, 2010), MAQ (Li et al., 2008), Novoalign3,
and SOAP (Li et al., 2009c). There are many others that are more
computationally intensive and are less frequently used. The per-
formance of different alignment methods has been extensively
studied (Bao et al., 2011; Ruffalo et al., 2011; Pattnaik et al., 2012).
They are based on either hash tables or the Burrows–Wheeler
transform (BWT; Burrows andWheeler, 1994). The former hashes
short reads or the reference genome into memory, while the
3http://novocraft.com
latter compresses data features by creating an index of the refer-
ence genome to allow fast access of potential alignment locations
(Nielsen et al., 2011). In general, BWT-based methods are faster
and more memory-efﬁcient. For instance, the BWA approach,
based on BWT, provides a good balance between speed, memory
usage, and accuracy, and is currently one of the most commonly
used methods for alignment in sequencing projects.
As the current NGS technologies use PCR-like ampliﬁcation
steps in the library preparation, multiple reads originating from
the same template could be sequenced. Overrepresentation of cer-
tain alleles due to ampliﬁcation bias introduced during library
construction tends to interfere with variant calling. For this rea-
son, it is common to remove PCR duplicates after alignment in
exome or whole-genome sequencing studies.
VARIANT CALLING
After alignment of short reads to the reference genome, the next
step in the bioinformatics process is variant identiﬁcation. Cur-
rently the sequencing error rate is estimated to be about 1%,which
is at a similar scale of the frequency of rare variants or higher.
For genotype calling, the presence of sequencing error poses a
computational challenge for the identiﬁcation of true variants.
Early generations of genotype calling methods counted allele at
each position and used simple cutoff values to determine when
to call a SNP. More recent probabilistic methods, such as MAQ
(Li et al., 2008) and SOAPsnp (Li et al., 2009b), use ﬁxed prior
values for modeling heterozygote probability as well as sequenc-
ing error, and make genotype calls based on posterior genotype
probabilities. Currently, some widely used variant calling methods
include SAMtools (Li et al., 2009a), the Genome Analysis ToolKit
(GATK, McKenna et al., 2010), and Atlas2 (Challis et al., 2012).
SAMtools builds upon a revised MAQ model to perform com-
putation of genotype likelihood and SNP calling. GATK utilizes
the MapReduce (Dean and Ghemawat, 2008) functional program-
ming technique for variant calling, SNP ﬁltering, and quality
recalibration. Atlas2 employs a logistic regression model trained
on validated whole-exome sequencing data and has better power
to assess the quality of potential variants (Ji, 2012).
We conducted a comprehensive evaluation of the variant iden-
tiﬁcation methods using the exome sequencing data described in
the next section. Based on our comparisons, GATK in general
provided the highest quality of variant identiﬁcation (Liu et al.,
Unpublished data).
Insertion and deletion (Indel) mutations are another common
formof polymorphism. It requires gapped alignment andpair-end
sequence inference. Several software packages have beendeveloped
to identify indels, including Pindel, a pattern growth method; and
Dindel, a Bayesian approach. A detailed review on Indel calling
has been published by Neuman et al. (2012).
There are several issues that can complicate the variant calling
step. First, the presence of indels is a major source of false posi-
tive in variant identiﬁcation. Alignment algorithms that allow for
gapped alignments are preferred. Second, variable GC content in
short reads, error introduced by library preparation due to PCR
artifacts, and variable base quality scores can affect variant calling.
The original quality scores assigned by the sequencer machine
have been shown to be inaccurate and biased. Thus several SNP
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calling algorithms, like GATK and SOAPsnp, have recommended
recalibration of base quality scores, using various calibrated error
models to empirically estimate error rates for each base, in order
to improve variant call accuracy.
ANALYZING VARIANTS IN SEQUENCING
The main challenge of analyzing sequencing variants in human
diseases is to identify disease-related alleles (which may be new
mutations) accounting for a large number of non-pathogenic
polymorphisms in the genome (Bamshad et al., 2011). Strate-
gies for ﬁnding causal variants differ between Mendelian and
complex diseases. Currently, successes in serious Mendelian disor-
ders through exome sequencing rely on various heuristic ﬁltering
methods to reduce the number of candidate genes. First, the
complete penetrance of a trait is usually assumed, i.e., all car-
riers of a disease-causing variant will have the phenotype. Any
variants present in public databases such asHapMap (The Interna-
tional HapMap Consortium, 2005, 2007), 1000 Genomes Project
(Abecasis et al., 2010), and dbSNP (Sherry et al., 2001) will be
excluded from further consideration. Then on the basis of the
mode of inheritance, for example, a recessive model, the list of
candidate variants can be further reduced. This has successfully led
to the identiﬁcation of rare causal variants in more than 10 studies
of recessive disorders. However, this type of ﬁltering has certain
limitations. Restricting the candidate variants to those not in pub-
lic databases in the ﬁrst ﬁltering step could result in exclusion of
possible pathogenic variants in the database, an especially note-
worthy problem for the mapping of recessive traits. In addition,
ﬁltering based on complete penetrance can eliminate variants that
are segregating in the population at low frequencies. Therefore
more sophisticated analytical and ﬁltering procedures that take
into account the minor allele frequency (MAF) of the risk variant
hold great promise to ﬁnding causal genes in Mendelian disorders
(Stitziel et al., 2011).
To identify likely causal variants in complex traits, associa-
tion tests are commonly employed. Sequencing studies enable
us to investigate rare variants association with a trait under the
assumption that multiple rare variants constitute the driving force
for the trait of interest. The association with rare variants poses
new statistical challenges. Power to detect an association with
an individual rare variant can be very low because only a small
percentage of study subjects carry a rare variant. To increase sta-
tistical power, many groups have investigated aggregating sets of
rare variants within a gene or genomic region to enrich associ-
ation signals (Li and Leal, 2008; Madsen and Browning, 2009;
Han and Pan, 2010; Morris and Zeggini, 2010; Price et al., 2010;
Ionita-Laza et al., 2011; Lin and Tang, 2011; Wu et al., 2011), and
recent studies show that power to detect rare variant effects can
be greatly enhanced. A comprehensive review on the statistical
methodology of sequence-based association studies is described by
Ionita-Laza et al. (2013). Another important aspect in sequencing-
based association studies is the choice of an appropriate study
design. Population-based and family-based designs are the two
most commonly used approaches in genetic association studies.
For rare variants with large effect size, family-based designs can
be advantageous because a particular rare variant found in an
affected individual, if it is not a new mutation, is more common in
that individual’s family than in subjects randomly sampled in the
population; this design can therefore potentially enrich for genetic
effects. Trio designs, and some other family designs, are also robust
to population structure (Ott et al., 2011). However, it can be more
difﬁcult to ascertain samples for family-based designs compared to
population-based designs. For different study designs, the analyt-
ical strategy for rare variant association needs to be chosen accor-
dingly.
Above, we describe a general framework of computation and
bioinformatics for handling sequencing data. Next we demon-
strate data quality and agreement between exome sequencing and
exome microarray (chip) genotypes using our data collected on
the same set of subjects in a genetic study of panic disorder.
DATA DESCRIPTION
We studied whole exome sequencing data on 20 patients of panic
disorder collected at Connecticut VA Medical Center (VAMC).
Twelve of thesewere from a single pedigree of ﬁve generationswith
more than 70 family members (not all of whom could be geno-
typed), and the rest were unrelated. All patients gave informed
consent approved by the institutional review boards at Yale and
CT VAMC. We studied all samples by exome capture using the
NimbleGen SeqCap EZ exome v2.0 kit, which targets 44.1 Mb of
the genome by design; samples were sequenced at the Yale Cen-
ter for Genome Analysis (YCGA). DNA fragments from the 20
samples were barcoded and sequenced on ﬁve lanes of a ﬂowcell
(four samples per lane). The exome sequence data were 74-base
paired-end reads generated from the Illumina HiSeq system.
Reads were aligned to the UCSC reference human genome
assembly hg19 using the sequence alignment software BWA ver-
sion 0.6.1 with the default parameters. The mapping ﬁles in SAM
format were converted to the BAM format and sorted by SAMtools
version 0.1.18. Local realignment around the known indels was
performed by GATK version 1.6.9 on the sorted BAM ﬁles. Picard
tools version 1.5.3 was used to remove PCR duplicates. Finally,
base quality score recalibration was performed using GATK. These
steps generated BAM ﬁles ready for variant calling. We used GATK
for variant identiﬁcation. Then the raw variants were ﬁltered using
VCFtools version 0.1.7.We further applied genotype ﬁltering using
depth ≥5 and genotype quality score ≥20 (Guo et al., 2012).
The 20 samples were also interrogated for 247,134 variants
using the Illumina HumanExome Beadchip genotyping microar-
ray. More than 90% of variants on the exome array fall in the
human RefSeq exons. The majority of them are non-synonymous
single nucleotide variations. The Illumina exome chip also con-
tains a small fraction of SNPs in splice sites, selected synonymous
SNPs, tag SNPs for previous GWAS hits in a variety of diseases,
and ancestry informative markers (AIMs). Eight samples failed
the genotyping quality control step were excluded from further
analysis.
RESULTS
On the 20 samples, we obtained an average of 48.7 (range 31.0–
77.6) million reads per subject, with 93× mean depth in the target
regions. The total length of the target region was 47.1 Mb, of
which 34.1 Mb were exomic. On average, 95.9% (94.3–97.2%)
of reads were mapped to the human reference genome. After
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removal of PCR duplicates, 90.7% (87.4–93.0%) of reads were
retained. Among those uniquely mapped, 58.8% (55.7–62.9%) of
reads were within the exonic regions. This proportion is similar
to the numbers reported for Agilent’s SureSelect v1 and Illumina’s
TrueSeq capture kits (Guo et al., 2012). The coverage for the target
regions was as follows: 40.6 Mb (57.9%) had coverage of at least
1×, 33.9 Mb (48.4%) had coverage of at least 10×, and 32.4 Mb
(46.3%) had coverage of at least 15×. For sequences outside the
target region, 209.8 Mb were covered by at least 1 read, 40.5 Mb
were covered by at least 10 reads, and 33.9 Mb were covered by at
least 15 reads. The comparison of the average read depth inside
and outside of the targeted exome is displayed in Figure 1. As we
expected, the depth of coverage in the exome regions was higher
in most regions due to target enrichment. An interesting feature
regarding read depth is that it varied across subjects in the target
regions, but stayed similar outside the target regions.
After applying GATK and variant ﬁltering, we identiﬁed an
average of 26,082 (24,122–28,058) variants per subject inside the
target regions, with Ti/Tv ratio of 2.85 (2.80–2.95). In addition, we
observed an average of 63,760 (51,414–83,835) variants per subject
outside the target regions, with Ti/Tv ratio of 2.17 (2.14–2.20).
These results are close to the reports that the expected Ti/Tv ratio
is around 3.0 for variants inside exons and about 2.0 elsewhere
(Bainbridge et al., 2011). The median quality score of variants
inside the target regions is 875.4, more than twice of the median
quality score of 340.0 outside the target regions. Based on the
distribution of variant quality scores inside and outside the target
regions (Figure 2), the variants identiﬁedwithin the exome regions
are of higher quality relative to those outside the target regions.
Besides variant quality score, another way to measure data
quality for sequence-based variant calling is to investigate geno-
type concordance using an alternative genotyping platform. We
use the exome microarray data for this purpose. Among the 12
subjects passed quality control on exome arrays, we identiﬁed
32,616 (13.2%) variant sites that showed at least one variation,
i.e., at least one subject had a heterozygous genotype (denoted
by 0/1) or homozygous rare allele genotype (denoted by 1/1).
We compared concordance between the array genotypes and the
FIGURE 1 | Mean read depth inside the target regions and outside the
target regions on the 20 sequenced subjects.
FIGURE 2 | Boxplot of identified variant quality scores inside the target
regions and outside the target regions.
sequence-based genotype calls. We calculated the genotype consis-
tency rate between exome sequence-based and exome chip-based
SNP calls for variants overlapping the two platforms in our sam-
ples. We used two types of consistency rate: overall consistency
and heterozygous variant consistency. Heterozygous consistency
rate was deﬁned as the ratio between the number of heterozygous
genotypes consistent between exome chip and exome sequenc-
ing and the number of heterozygous genotypes on the exome
chip that had sequence-based calls with genotype quality score
≥20 and depth ≥5. The results for the 12 subjects are shown in
Table 1. The overall consistency rate with array-based variant calls
Table 1 | Results of genotype consistency between exome sequencing
and exome chip on 12 subjects.
Consistent genotypes Consistency rate
Subject 0/0 0/1 1/1 Overall Heterozygous
(%) (%)
1 218523 4686 2949 99.84 98.28
2 220203 4860 3092 99.83 98.56
4 218043 4608 3016 99.87 97.88
5 218478 4654 2976 99.84 98.21
6 218463 4685 2870 99.83 98.07
7 218553 4765 2999 99.85 97.96
8 214082 4625 2815 99.86 97.55
9 219050 4888 2892 99.87 98.33
15 218233 4719 2995 99.85 98.25
16 217804 4579 3024 99.83 97.99
17 217440 4654 2931 99.84 98.39
19 219067 4566 3025 99.83 98.26
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was >99.83% in all samples, and the heterozygous consistency
rate was 98.14% (97.55–98.56%). The actual overall consistency
rate is higher because we observed a large portion of concordant
genotype calls between these two platforms falling in the category
of homozygous reference genotypes. On average, more genotype
calling errors would occur when the underlying genotype contains
the allele that is not the reference allele. Depending on the pur-
pose of the study, for example, in gene-trait association studies,
the goal is usually to search for putative rare variants that could
be causal for the trait; then, the heterozygous SNP calls would
be more informative and the consistency measure based on het-
erozygous SNPs would be more representative of the true error
rate. We also found that the consistency rate in the 1/1 genotype
category was similar to the heterozygous consistency rate in our
dataset.
Overall, the genotype calls generated by exome sequencing and
exome genotyping arrays showed high agreement in all the 12
samples.
DISCUSSION
Wehave provided anoverviewof the applicationof exome-focused
NGS technologies in human diseases. The growing number
of exome sequencing studies demonstrates the power of this
approach in mapping genes involved in Mendelian disorders and
suggests utility for complex traits as well. In many successful
studies, a small number of individualswas analyzed, andoften only
affected individuals have been sequenced. However, there are still a
large number of Mendelian diseases with unknown genetic causes.
Although exome sequencing has generated high-quality data
for single nucleotide variant detection with sufﬁcient depth of
coverage, it is still difﬁcult to detect accurately indels with short
sequence reads generated byNGS technologies. In addition, exome
sequencing is not suitable for the identiﬁcation of structural
variants and chromosomal rearrangements that may involve non-
exonic sequence. Furthermore, as the current sequence capturing
methods suffer from theproblemof uneven and incomplete exonic
region capture (Parla et al., 2011), potentially interesting muta-
tions in these exonic regions could be missed. This will likely be
solved in the future when the cost of whole-genome sequencing is
lower.
Studies of genetically complex traits have also beneﬁted from
exome sequencing since the advent of NGS technologies. Although
the small sample sizes that can be used in Mendelian diseases are
underpowered for detecting association using currently available
association tests for complex traits, we can still gain insight by
studying small cohorts from the extreme ends of the phenotypic
spectrum of common traits, and as costs come down, well pow-
ered studies of complex traits via exome sequencing have become
feasible. This has been demonstrated by a successful example of
a whole exome sequencing study of patients with extremely low
levels of low-density lipoprotein (LDL) cholesterol (Musunuru
et al., 2010). The ﬁndings of risk alleles in GWAS typically cannot
pinpoint causal variants, but exome sequencing studies enable
more accurate and complete variant discovery (of course this is
under the assumption that the risk variant is exomic) and allow
for, in theory, the direct association between phenotype and causal
variant. They have provided a new mechanistic perspective on the
development of the complex disease gene mapping paradigm.
Currently, with sequencing data, there is still a strong demand
for more powerful and efﬁcient analytic methods for novel gene
discovery in the analysis of complex diseases.
We demonstrated the high quality of exome sequencing data in
our samples collected from a study of panic disorder. We exam-
ined SNP quality within and outside the targeted exome regions.
With the NimbleGen SeqCap capturing method, about 59% of
the reads in our dataset were mapped within the target regions,
meaning and there are still a signiﬁcant number of reads that map
elsewhere. About 30% of reads fall outside >200 bp of the exonic
region, and 10% of reads are within 200 bp from the nearest tar-
get region. Variant call qualities were generally better for positions
within the target regions, due to successful target enrichment.
Furthermore, we computed genotype concordance with exome
microarray data. The overall consistency rate was >99.83% and
the heterozygous consistency rate was 98.14%, which suggests that
the two platforms maintained a large amount of agreement over
low frequency variants in the exonic regions.
Undoubtedly, the data generated in NGS technologies will con-
tinue to grow in terms of the depth per individual and the number
of samples per dollar. The role of computation and bioinformatics
becomes more and more crucial in the analysis and interpretation
of sequencing data. Tremendous effort has been devoted to the
development of tools for variant analysis in the process of quality
control, alignment, variant identiﬁcation, and downstream associ-
ation studies. As whole-genome sequencing becomes prevalent in
the next few years, future developments of workﬂow and pipelines
will facilitate researches on human diseases.
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